Eli Lilly and Novo Nordisk set to share obesity drug market, with sales expected to exceed $120 billion by 2030
Reported by Consejeros Editorial Team The global market for obesity drugs is entering a new phase of expansion outside the United States, driven by Eli Lilly, which is seeking to broaden access to its flagship treatments in the face of the US market’s increasing saturation. Bloomberg Intelligence estimates that global sales of obesity drugs will exceed $120 billion by 2030, with Eli Lilly positioning itself as the main beneficiary. For…









